Takeda To Challenge U.S. Jury's $9 Billion Fine In Actos Drug Suit
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it would appeal the order by a U.S. District Court that together with and Eli Lilly pay $9 billion in punitive damages for failure to disclose the adverse risks of its Actos (pioglitazone) diabetes drug.